A Phase 3 interventional study of Investigational live attenuated varicella vaccine and diluent of lyophilized vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Completed at 2 sites in China. Open to participants aged 1 Year to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.
Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 22nd registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 1 Year to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,997 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sinovac (Dalian) Vaccine Technology Co., Ltd., one of the names counted as Sinovac Biotech Co., Ltd. Under that name alone:
Sinovac (Dalian) Vaccine Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.
17 studies in Chickenpox by Sinovac Biotech Co., Ltd: 7 open now, 7 under way, 3 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 17 studies in Chickenpox by Sinovac Biotech Co., Ltd, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 2nd registered.
Sinovac Biotech Co., Ltd’s Chickenpox studies by the year they started, since 2014.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinovac Biotech Co., Ltd’s 17 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.
This study is a randomized, blind, controlled phase III clinical trial. The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Receipt of any of the following products:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0; * Intervention: investigational live attenuated varicella vaccine;
Biological: Investigational live attenuated varicella vaccine
* Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0; * Intervention: diluent of lyophilized vaccine;
Biological: diluent of lyophilized vaccine
The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
The incidences of varicella of each group
The first 30 cases of varicella occurred 30 days after injection will be collected.
Time frame: ≥30 cases reported 30 days after injection
The protection rate of the vaccine
The protection rate will be calculated based on the reported cases occurred 30 days after injection.
Time frame: ≥30 cases reported after 30 days of the injection
The incidences of adverse events (AEs) of each group
AEs occurred within 30 days after injection will be collected.
Time frame: 30 days
The incidences of serious adverse events (SAEs) of each group
SAEs occurred within 6 months after injection will be collected.
Time frame: 6 months
The seroconversion rate of the immunogenicity group
Seroconversion rate of the immonogenicity group 30 days after injection will be collected.
Time frame: 30 days after injection
The geometric mean titer (GMT) of the immunogenicity group
Geometric mean titer (GMT) of the immonogenicity group will be collected before and 30 days after injection.
Time frame: 30 days
The geometric mean fold increase (GMI) of the immunogenicity group
Geometric mean fold increse (GMI) of the immonogenicity group will be calculated based on the geometric mean titer.
Time frame: 30 days after injection
Plan to share: No
Ran from Aug 2016 to primary completion in Jun 2017, 10 months.
Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 10 months is below that.
Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd. →